search
Back to results

AVocAdo Extract to Improve gLycemia in Individuals With Obesity (AVAIL)

Primary Purpose

Obesity

Status
Completed
Phase
Not Applicable
Locations
Australia
Study Type
Interventional
Intervention
Avocado extract
Placebo
Sponsored by
University of Adelaide
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Obesity focused on measuring Obesity, Avocado extract, Cardiometabolic health

Eligibility Criteria

25 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Men and women 25 - 65 years old
  • Waist circumference (>94cm in men and >80cm in women)
  • BMI 30 - 40 kg/m2
  • Willingness to provide written informed consent and willingness to participate and comply with the study

Exclusion Criteria:

  • Women planning pregnancy during the course of the study or 3 months after completion of the study, or who are lactating
  • Individuals diagnosed with type 1 or type 2 diabetes mellitus, liver or kidney diseases, neoplastic disease in the previous 3 years, chronic gastrointestinal disorders (including inflammatory bowel disease and celiac), cardiovascular event in the previous 6 months, or any other condition deemed unstable
  • Biochemical abnormalities or evidence at screening of disease including elevated liver enzymes ALT and/or AST >3 times normal range limit
  • Not weight-stable (< 5 % fluctuation in their body weight for past 6-months at study entry).
  • Current or recent (within 12 months) treatment with medication used to lower blood glucose or antidiabetic medications (metformin, sulfonylureas, glucagon-like peptide-1 (GLP-1) analogues [i.e. exenatide], thiazolidinediones or DPP-IV inhibitors [i.e. 'gliptins']), medications affecting weight, appetite or gut motility (i.e. domperidone, cisapride, orlistat, phentermine, topiramate). Participants who are taking stable doses (i.e. > 12 months) of androgenic medications (i.e. testosterone), thyroxine, corticosteroids, anti-depressants (selective serotonin reuptake inhibitors), anti-hypertensives (ace-inhibitors, calcium channel blockers, beta-blockers, diuretics) and lipid lowering medications (statins, fibrates) will not be excluded.
  • Participants who have had bariatric surgery
  • Participants with conditions that may interfere with the ability to understand the requirements of the study.

Sites / Locations

  • The University of Adelaide

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Placebo

Avocado extract

Arm Description

Participants will consume 10 grams of corn meal daily for 12 weeks.

Participants will consume 10 grams of freeze dried avocado daily for 12 weeks.

Outcomes

Primary Outcome Measures

Glycemic response
Change in glucose area under the curve (AUC) in response to 75 g oral glucose tolerance test

Secondary Outcome Measures

Fasting glucose
Change in fasting glucose
Fasting insulin
Change in fasting insulin
Postprandial insulin
Change in insulin AUC in response to 75g oral glucose tolerance test
Homeostatic model assessment of insulin resistance (HOMA-IR)
Change in HOMA-IR
Body weight
Change in body weight
Waist circumference
Change in waist circumference
Body composition
Change in body composition assessed by dual-energy X-ray absorptiometry (DEXA)
Blood pressure
Change in systolic and diastolic blood pressure
Blood lipids
Change in total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglycerides
C-reactive protein
Change in blood C-reactive protein
Oxidative stress
Change in blood isoprostane
Autophagy
Changes in blood mRNA levels of autophagy markers

Full Information

First Posted
February 16, 2021
Last Updated
April 6, 2023
Sponsor
University of Adelaide
Collaborators
Isagenix International LLC, Commonwealth Scientific and Industrial Research Organisation, Australia, Prolongevity Technologies
search

1. Study Identification

Unique Protocol Identification Number
NCT04763473
Brief Title
AVocAdo Extract to Improve gLycemia in Individuals With Obesity (AVAIL)
Official Title
AVocAdo Extract to Improve gLycemia in Individuals With Obesity (AVAIL)
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
March 9, 2021 (Actual)
Primary Completion Date
August 11, 2022 (Actual)
Study Completion Date
August 11, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Adelaide
Collaborators
Isagenix International LLC, Commonwealth Scientific and Industrial Research Organisation, Australia, Prolongevity Technologies

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This two-arm, double blind, randomized clinical trial will compare the effect of an avocado extract, compared to placebo, on cardiometabolic outcomes in adults with obesity.
Detailed Description
Sixty eligible participants will be stratified by sex and randomly assigned to placebo or avocado extract supplementation group for 12 weeks. Metabolic testing will be performed at baseline, and at the end of the intervention.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Obesity, Avocado extract, Cardiometabolic health

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants will consume 10 grams of corn meal daily for 12 weeks.
Arm Title
Avocado extract
Arm Type
Experimental
Arm Description
Participants will consume 10 grams of freeze dried avocado daily for 12 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
Avocado extract
Intervention Description
Participants will consume 10 grams of freeze dried avocado daily for 12 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
Participants will consume 10 grams of corn meal daily for 12 weeks.
Primary Outcome Measure Information:
Title
Glycemic response
Description
Change in glucose area under the curve (AUC) in response to 75 g oral glucose tolerance test
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Fasting glucose
Description
Change in fasting glucose
Time Frame
12 weeks
Title
Fasting insulin
Description
Change in fasting insulin
Time Frame
12 weeks
Title
Postprandial insulin
Description
Change in insulin AUC in response to 75g oral glucose tolerance test
Time Frame
12 weeks
Title
Homeostatic model assessment of insulin resistance (HOMA-IR)
Description
Change in HOMA-IR
Time Frame
12 weeks
Title
Body weight
Description
Change in body weight
Time Frame
12 weeks
Title
Waist circumference
Description
Change in waist circumference
Time Frame
12 weeks
Title
Body composition
Description
Change in body composition assessed by dual-energy X-ray absorptiometry (DEXA)
Time Frame
12 weeks
Title
Blood pressure
Description
Change in systolic and diastolic blood pressure
Time Frame
12 weeks
Title
Blood lipids
Description
Change in total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglycerides
Time Frame
12 weeks
Title
C-reactive protein
Description
Change in blood C-reactive protein
Time Frame
12 weeks
Title
Oxidative stress
Description
Change in blood isoprostane
Time Frame
12 weeks
Title
Autophagy
Description
Changes in blood mRNA levels of autophagy markers
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Men and women 25 - 65 years old Waist circumference (>94cm in men and >80cm in women) BMI 30 - 40 kg/m2 Willingness to provide written informed consent and willingness to participate and comply with the study Exclusion Criteria: Women planning pregnancy during the course of the study or 3 months after completion of the study, or who are lactating Individuals diagnosed with type 1 or type 2 diabetes mellitus, liver or kidney diseases, neoplastic disease in the previous 3 years, chronic gastrointestinal disorders (including inflammatory bowel disease and celiac), cardiovascular event in the previous 6 months, or any other condition deemed unstable Biochemical abnormalities or evidence at screening of disease including elevated liver enzymes ALT and/or AST >3 times normal range limit Not weight-stable (< 5 % fluctuation in their body weight for past 6-months at study entry). Current or recent (within 12 months) treatment with medication used to lower blood glucose or antidiabetic medications (metformin, sulfonylureas, glucagon-like peptide-1 (GLP-1) analogues [i.e. exenatide], thiazolidinediones or DPP-IV inhibitors [i.e. 'gliptins']), medications affecting weight, appetite or gut motility (i.e. domperidone, cisapride, orlistat, phentermine, topiramate). Participants who are taking stable doses (i.e. > 12 months) of androgenic medications (i.e. testosterone), thyroxine, corticosteroids, anti-depressants (selective serotonin reuptake inhibitors), anti-hypertensives (ace-inhibitors, calcium channel blockers, beta-blockers, diuretics) and lipid lowering medications (statins, fibrates) will not be excluded. Participants who have had bariatric surgery Participants with conditions that may interfere with the ability to understand the requirements of the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Leonie Heilbronn
Organizational Affiliation
The University of Adelaide
Official's Role
Principal Investigator
Facility Information:
Facility Name
The University of Adelaide
City
Adelaide
State/Province
South Australia
ZIP/Postal Code
5000
Country
Australia

12. IPD Sharing Statement

Learn more about this trial

AVocAdo Extract to Improve gLycemia in Individuals With Obesity (AVAIL)

We'll reach out to this number within 24 hrs